Halozyme director Mahesh Krishnan disposes of 7,304 shares for $547,800

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.

HALO

0.00
  • Halozyme director Mahesh Krishnan sold 7,304 common shares on June 29, 2026 at USD 75.
  • Sale followed the exercise of options for 7,304 shares at USD 38.46.
  • He held 14,462 shares directly after the transactions.
  • He also reported 1,500 options to purchase common stock outstanding.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000082), on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.